Bull, Bear & Beyond – OSE Immunotherapeutics: executive interview

In this interview, Sonya Montgomery, chief development officer at OSE Immunotherapeutics, covers the company’s lead immuno-inflammation candidate, lusvertikimab. She outlines the current unmet need in the therapeutic areas of ulcerative colitis and inflammatory bowel disease, as well as lusvertikimab’s clinical track record to date. She also discusses potential next steps for the programme, including OSE’s recently announced predictive biomarker, the potential of lusvertikimab to overcome the current therapeutic ceiling, and what a precision medicine approach might look like. She concludes by highlighting the key upcoming catalysts and milestones that investors should watch out for.

Listen on your preferred podcast player below:

• Apple Podcast
• Spotify
• YouTube
• Zencastr

About Bull, Bear & Beyond: Each episode features candid conversations with senior executives and from our own team of experts from across industries, exploring strategy, innovation, and the opportunities shaping their markets and 60-second pieces are a compressed summary of content designed to convey our message in a single, easily shareable hit.